Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains
  1. Home
  3. Research Domains

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Autocrine Pdgfr Signaling Promotes Mammary Cancer Metastasis.
  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Autocrine Pdgfr Signaling Promotes Mammary Cancer Metastasis.

    • Related Experiment Videos

    Autocrine PDGFR signaling promotes mammary cancer metastasis.

    Martin Jechlinger1, Andreas Sommer, Richard Moriggl

    • 1Research Institute for Molecular Pathology, Vienna, Austria.

    The Journal of Clinical Investigation
    |June 3, 2006

    View abstract on PubMed

    Summary
    This summary is machine-generated.

    Targeting the platelet-derived growth factor receptor (PDGFR) pathway can inhibit cancer metastasis. This study reveals PDGFR signaling is crucial for epithelial-mesenchymal transition (EMT) and tumor cell survival, offering new therapeutic strategies.

    Related Experiment Videos

    Area of Science:

    • Oncology
    • Cell Biology
    • Molecular Medicine

    Background:

    • Metastasis is a primary driver of cancer mortality, with limited therapeutic strategies targeting invasion.
    • Dedifferentiated tumor cells secrete factors that are potential therapeutic targets.

    Purpose of the Study:

    • To investigate the role of autocrine platelet-derived growth factor (PDGF)/PDGF receptor (PDGFR) signaling in cancer metastasis.
    • To explore the potential of PDGFR inhibition as a therapeutic strategy against metastasis.

    Main Methods:

    • Investigated the PDGF/PDGFR loop in oncogenic mammary epithelial cells undergoing TGF-beta-induced epithelial-mesenchymal transition (EMT).
    • Assessed the effects of PDGFR inhibition using dominant-negative PDGFR and the drug STI571 in vitro and in vivo.
    • Analyzed PDGFRalpha and -beta expression in human mammary carcinomas.

    Main Results:

    • Autocrine PDGFR signaling is required for survival during EMT, cooperating with oncogenic Ras to hyperactivate PI3K.
    • PDGFR inhibition induced apoptosis and interfered with EMT in murine and human mammary carcinoma cells.
    • STI571 treatment inhibited experimental metastasis in mice and PDGFR expression correlated with invasiveness in human cancers.

    Conclusions:

    • Autocrine PDGFR signaling is essential for cancer progression and metastasis.
    • Inhibiting PDGFR signaling represents a novel therapeutic approach to combat metastasis.
    • The drug STI571 shows promise for interfering with metastatic processes.